Lexeo Therapeutics, Inc. (LXEO)
NASDAQ: LXEO · Real-Time Price · USD
6.28
+0.24 (3.97%)
Dec 20, 2024, 4:00 PM EST - Market closed
Lexeo Therapeutics Employees
Lexeo Therapeutics had 58 employees as of December 31, 2023. The number of employees increased by 34 or 141.67% compared to the previous year.
Employees
58
Change
34
Growth
141.67%
Revenue / Employee
n/a
Profits / Employee
-$1,493,034
Market Cap
207.65M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 58 | 34 | 141.67% |
| Dec 31, 2021 | 24 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Inogen | 834 |
| SOPHiA GENETICS | 430 |
| MacroGenics | 339 |
| ADC Therapeutics | 274 |
| Biodesix | 217 |
| Inhibrx Biosciences | 172 |
| Inventiva | 123 |
| Atai Life Sciences | 83 |
LXEO News
- 2 days ago - Lexeo Therapeutics Appoints Kyle Rasbach as Chief Financial Officer - GlobeNewsWire
- 5 weeks ago - Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 7 weeks ago - Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer's Disease, at the Clinical Trials on Alzheimer's Disease (CTAD) Conference - GlobeNewsWire
- 2 months ago - Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Conference - GlobeNewsWire
- 3 months ago - Lexeo Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights - GlobeNewsWire
- 5 months ago - Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further - Seeking Alpha
- 5 months ago - Nasdaq Surges Over 1%; Lexeo Therapeutics Shares Plummet - Benzinga